Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer

Current Treatment Options in Oncology

Volumn 13, Issue 2, 2012, Pages 174-188

  Autio, Karen A ^a   Scher, Howard I ^a   Morris, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone metastases; Bone directed therapy; Radiopharmaceuticals; Skeletal related events

Indexed keywords

ABIRATERONE; BEVACIZUMAB; CABAZITAXEL; CABOZANTINIB; CALCIUM; CYTOTOXIC AGENT; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RILOTUMUMAB; SAMARIUM 153; SCATTER FACTOR RECEPTOR; SIPULEUCEL T; STRONTIUM 89; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZIBOTENTAN; ZOLEDRONIC ACID;

ALPHA RADIATION; ARTICLE; BETA RADIATION; BLOOD TOXICITY; BONE FRAGILITY; BONE MARROW SUPPRESSION; BONE METABOLISM; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; DISEASE ASSOCIATION; DRUG EXCRETION; DRUG HALF LIFE; FATIGUE; FEBRILE NEUTROPENIA; FRACTURE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OSTEOBLAST; OSTEOCLAST; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN MANAGEMENT; PROSTATIC NEOPLASMS; STRONTIUM;

EID: 84863717293     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0190-8     Document Type: Article

References (67)

1. Coleman R. Management of bone metastases. Cancer Treat Rev. 1997;23 Suppl 1:S69-75.
2. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29(27):3705-14.
3. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27 (15):2429-35.
4. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: Quality-of-life considerations throughout the continuum of care. Eur Urol. 2004;46(6):731-39. discussion 739-40.
5. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377 (9768):813-22. This large, randomized, non-inferiority trial demonstrated that denosumab delayed skeletal-related events by 3.6 months relative to zoledronic acid in men with mCRPC. Both agents are FDA approved to delay skeletal events in metastatic castration-resistant disease.
6. Saad F, Gleason DM, Murray R, et al. Long-Term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351 (15):1502-12.
8. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376(9747):1147-54.
9. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-59.
10. US Dept of Health and Human Services, Food and Drug Administration. Guidance for industry: Patientreported outcome measures: Use in medical product development to support labeling claims. 2010. http://www.fda.gov/downloads/ Drugs/GuidanceComplian ceRegulatoryInformation/Guidances/UCM193282. pdf. Accessed 1 Mar 2012.
11. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival inmen with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46.
12. Furlow B. US FDA advisory panel rejects early denosumab therapy. Lancet Oncol. 2012;13(3):e94.
13. Pradhan SM. FDA Presentation sBLA 125320/28 Xgeva™ (denosumab). Food and Drug Administration, Oncology Drugs Advisory Committee Briefing Document, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf. Accessed 1 Mar 2012.
14. Guise T. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol. 2010;37 Suppl 2:S2-14.
15. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68.
16. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9(1):295-306.
17. Brubaker KD, Brown LG, Vessella RL, et al. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer. 2006;6:15.
18. Hung TT, Chan J, Russell PJ, et al. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One. 2011;6(5):e19389.
19. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349 (17):1676-9. discussion 1676-9.
20. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebocontrolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-84.
21. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011.
22. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008-12.
23. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038-42.
24. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9.
25. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.
26. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361 (8):745-55. This placebo-controlled randomized phase III study established that denosumab can mitigate the bone-wasting effects of androgen-deprivation therapy in prostate cancer patients. Bone density improved and fracture rates were reduced with the use of denosumab.
27. Smith HS. Painful osseous metastases. Pain Physician. 2011;14(4):E373-403.
28. Taylor Jr AJ. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med. 1994;35 (12):2054.
29. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25(10):1362-7.
30. Turner SL, Gruenewald S, Spry N, et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001;84(3):297-302.
31. Baczyk M, Milecki P, Baczyk E, et al. The effectivness of strontium 89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil. 2003;5(3):364-8.
32. Gunawardana DH, Lichtenstein M, Better N, et al. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004;29(2):81-5.
33. Tu SM, Millikan RE, Mengistu B, et al. Bone-Targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet. 2001;357:326-7.
34. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997;24(10):1210-4.
35. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol. 2005;6(6):392-400.
36. Robinson RG, Preston DF, Baxter KG, et al. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol. 1993;20:44-8.
37. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent pros-Tate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23(31):7904-10.
38. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991;64:816-22.
39. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926-31.
40. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebocontrolled clinical trial. J Clin Oncol. 1998;16 (4):1574-81.
41. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109(3):637-43.
42. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940-5.
43. Resche I, Chatal J-F, Pecking A, et al. A dose-controlled study of 153-Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-91.
44. Tu SM, Mathew P, Wong FC, et al. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27 (20):3319-24.
45. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436-42.
46. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-64.
47. Osoba D, Tannock IF, Ernst S, et al. Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999; 17(6):1654-63.
48. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;18(8):2506-13.
49. Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24 (18):2828-35.
50. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
51. Nilsson S, Franzen L, Parker C, et al. Bone-Targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebocontrolled phase II study. Lancet Oncol. 2007;8 (7):587-94.
52. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451-9.
53. Bruland OS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s-7s.
54. Parker C, Heinrich D, Sullivan JM, et al. Overall survival benefit of radium 223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castrate resistant prostate cancer: A phase III randomized trial. In: European Multidisciplinary Cancer Congress, Stockholm; 2011.
55. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized Phase II trial. BJU Int. 2010;106 (7):966-73.
56. Kelly WK HS, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol. 2010;28:18s. suppl; abstr LBA4511.
57. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113-7.
58. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147(2):386-96.
59. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915-25.
60. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251 (4995):802-4.
61. Hussain M SM, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011:29, suppl. Abstr 4516.
62. Saad F, Lipton A. SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev. 2010;36(2):177-84.
63. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer. 2011.
64. Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: Expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011;77 (5):1166-71.
65. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21): 1995-2005.
66. Tu SM, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996;2(6):191-7.
67. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.